Sector News

AstraZeneca divests gastrointestinal drug for $215 million

July 9, 2015
Life sciences
AstraZeneca struck a further “externalization” deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million.
 
The British drugmaker, which has high hopes for its new drug pipeline but faces declining sales as older products lose patent protection, said rights to Entocort outside the United States would be acquired by Tillotts Pharma, part of the Zeria Group.
 
Entocort, or budesonide, is used to treat patients with mild to moderate Crohn’s disease and ulcerative colitis. It is sold in more than 40 countries and had sales of $53 million outside the United States in 2014.
 
The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer, respiratory disease and diabetes.
 
Chief Executive Pascal Soriot argues that spinning off non-core businesses like Entocort will help the company’s finances and allow it to invest for the future, but some analysts are worried about its reliance on such deals.
 
The issue came to a head in April when AstraZeneca said it was getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers.
 
Soriot has also struck cash-generating externalization deals with Eli Lilly in Alzheimer’s and with Daiichi Sankyo for a new constipation drug.
 
(Reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach